Symeres Acquires Exemplify BioPharma

October 25, 2022

Symeres, a Netherlands-headquartered transatlantic CRO/CDMO majority‑owned by Keensight Capital, has acquired Exemplify BioPharma, a Cranbury, New Jersey-based CMC-focused CRO. The deal strengthens Symeres' capabilities in process and analytical chemistry and formulation development and further expands its strategic foothold in the United States.

Targets
Exemplify BioPharma
Platforms
Symeres
Industry
Pharmaceuticals
Location
New Jersey, United States
Transaction Type
Addon

Explore More

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.